EGFR and KRAS mutational analysis in a large series of Italian non-small cell lung cancer patients: 2,387 cases from a single center

Giannini,Riccardo; Lupi,Cristiana; Sensi,Elisa; Alì,Greta; Proietti,Agnese; Boldrini,Laura; Servadio,Adele; Giordano,Mirella; Macerola,Elisabetta; Bruno,Rossella; Borrelli,Nicla; Chella,Antonio; Melfi,Franca; Lucchi,Marco; Ribechini,Alessandro; Vasile,Enrico; Cappuzzo,Federico; Mussi,Alfredo; Fontanini,Gabriella

doi:10.3892/or.2016.4874

EGFR and KRAS mutational analysis in a large series of Italian non-small cell lung cancer patients: 2,387 cases from a single center

Authors:
- Riccardo Giannini
- Cristiana Lupi
- Elisa Sensi
- Greta Alì
- Agnese Proietti
- Laura Boldrini
- Adele Servadio
- Mirella Giordano
- Elisabetta Macerola
- Rossella Bruno
- Nicla Borrelli
- Antonio Chella
- Franca Melfi
- Marco Lucchi
- Alessandro Ribechini
- Enrico Vasile
- Federico Cappuzzo
- Alfredo Mussi
- Gabriella Fontanini
View Affiliations

Affiliations: Department of Surgical, Medical, Molecular Pathology and Critical Area, University of Pisa, Pisa, Italy, Unit of Anatomic Pathology 3, Azienda Ospedaliero‑Universitaria Pisana, Pisa, Italy, Unit of Pneumology, Azienda Ospedaliero‑Universitaria Pisana, Pisa, Italy, Unit of Thoracic Surgery, Azienda Ospedaliero‑Universitaria Pisana, Pisa, Italy, Unit of Thoracic Endoscopy, Azienda Ospedaliero‑Universitaria Pisana, Pisa, Italy, Unit of Medical Oncology 2, Azienda Ospedaliero‑Universitaria Pisana, Pisa, Italy, Medical Oncology Department, Istituto Toscano Tumori, Ospedale Civile, Livorno, Italy
Published online on: June 14, 2016 https://doi.org/10.3892/or.2016.4874
Pages: 1166-1172

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Activating EGFR mutations are important genetic alterations that have strong therapeutic implications for non-small cell lung cancer (NSCLC) patients. However, the role of KRAS mutations in this process is still under evaluation. Here, we report on the feasibility of a large‑scale EGFR and KRAS mutation analysis in the daily routine of a single center. NSCLCs from 2,387 patients were screened for EGFR and KRAS mutations from January 2010 to September 2015. Mutational analyses were performed in a single laboratory using single strand conformation polymorphism (SSCP)-Sanger sequencing and matrix‑assisted laser desorption ionization‑time of flight (MALDI‑TOF) on Sequenom platform for EGFR and pyrosequencing for KRAS. Activating EGFR mutations were found in 14.1% of all tumors, whereas KRAS mutations were found in 30.5% of all tumors. Direct sequencing showed analyzable cytological, small biopsy and surgical specimen percentages of 90.3, 90.9 and 98.1%, respectively, whereas the MALDI‑TOF platform showed analyzable cytological samples, small biopsies and surgical specimens percentages of 94.6, 95.7 and 96.9%, respectively. The mean analytical turnaround times (TAT) were 4 and 3 days for direct sequencing and the MALDI‑TOF platform, respectively. Our results confirm that small biopsy or cytological samples can be used for reliable EGFR and KRAS mutation testing and indicate that adopting the MALDI‑TOF platform reduces the rate of missed samples among the samples. Moreover, the 3-day analytical TAT of the MALDI-TOF multi-target technique is appropriate for clinical management and reduces the overall treatment decision time.

View Figures

View References

1	Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, Majem M, Lopez-Vivanco G, Isla D, Provencio M, et al Spanish Lung Cancer Group: Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 361:958–967. 2009. View Article : Google Scholar : PubMed/NCBI
2	Weber B, Hager H, Sorensen BS, McCulloch T, Mellemgaard A, Khalil AA, Nexo E and Meldgaard P: EGFR mutation frequency and effectiveness of erlotinib: A prospective observational study in Danish patients with non-small cell lung cancer. Lung Cancer. 83:224–230. 2014. View Article : Google Scholar : PubMed/NCBI
3	Krawczyk P, Ramlau R, Chorostowska-Wynimko J, Powrózek T, Lewandowska MA, Limon J, Wasąg B, Pankowski J, Kozielski J, Kalinka-Warzocha E, et al: The efficacy of EGFR gene mutation testing in various samples from non-small cell lung cancer patients: A multicenter retrospective study. J Cancer Res Clin Oncol. 141:61–68. 2015. View Article : Google Scholar :
4	Scarpino S, Pulcini F, Di Napoli A, Giubettini M and Ruco L: EGFR mutation testing in pulmonary adenocarcinoma: Evaluation of tumor cell number and tumor percent in paraffin sections of 120 small biopsies. Lung Cancer. 87:8–13. 2015. View Article : Google Scholar
5	Sherwood JL, Müller S, Orr MC, Ratcliffe MJ and Walker J: Panel based MALDI-TOF tumour profiling is a sensitive method for detecting mutations in clinical non small cell lung cancer tumour. PLoS One. 9:e1005662014. View Article : Google Scholar : PubMed/NCBI
6	da Cunha Santos G, Saieg MA, Geddie W and Leighl N: EGFR gene status in cytological samples of nonsmall cell lung carcinoma: Controversies and opportunities. Cancer Cytopathol. 119:80–91. 2011. View Article : Google Scholar : PubMed/NCBI
7	Eberhard DA, Giaccone G and Johnson BE; Non-Small-Cell Lung Cancer Working Group: Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: Standardization for use in the clinical trial setting. J Clin Oncol. 26:983–994. 2008. View Article : Google Scholar : PubMed/NCBI
8	Aisner DL, Deshpande C, Baloch Z, Watt CD, Litzky LA, Malhotra B, Sepulveda AR, Langer C, Evans T and Van Deerlin VM: Evaluation of EGFR mutation status in cytology specimens: An institutional experience. Diagn Cytopathol. 41:316–323. 2013. View Article : Google Scholar
9	Aisner DL and Marshall CB: Molecular pathology of non-small cell lung cancer: A practical guide. Am J Clin Pathol. 138:332–346. 2012. View Article : Google Scholar : PubMed/NCBI
10	Helland Å, Skaug HM, Kleinberg L, Iversen ML, Rud AK, Fleischer T, Sagerup C, Solberg S, Jørgensen L, Ariansen S, et al: EGFR gene alterations in a Norwegian cohort of lung cancer patients selected for surgery. J Thorac Oncol. 6:947–950. 2011. View Article : Google Scholar : PubMed/NCBI
11	Ludovini V, Bianconi F, Pistola L, Pistola V, Chiari R, Colella R, Bellezza G, Tofanetti FR, Siggillino A, Baldelli E, et al: Optimization of patient selection for EGFR-TKIs in advanced non-small cell lung cancer by combined analysis of KRAS, PIK3CA, MET, and non-sensitizing EGFR mutations. Cancer Chemother Pharmacol. 69:1289–1299. 2012. View Article : Google Scholar : PubMed/NCBI
12	Rotella V, Fornaro L, Vasile E, Tibaldi C, Boldrini L, Chella A, D'Incecco A, Cirigliano G, Chioni A, Lupi C, et al: EGFR and K-Ras mutations in women with lung adenocarcinoma: Implications for treatment strategy definition. J Exp Clin Cancer Res. 33:772014. View Article : Google Scholar : PubMed/NCBI
13	Gahr S, Stoehr R, Geissinger E, Ficker JH, Brueckl WM, Gschwendtner A, Gattenloehner S, Fuchs FS, Schulz C, Rieker RJ, et al: EGFR mutational status in a large series of Caucasian European NSCLC patients: Data from daily practice. Br J Cancer. 109:1821–1828. 2013. View Article : Google Scholar : PubMed/NCBI
14	Marchetti A, Martella C, Felicioni L, Barassi F, Salvatore S, Chella A, Camplese PP, Iarussi T, Mucilli F, Mezzetti A, et al: EGFR mutations in non-small-cell lung cancer: Analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol. 23:857–865. 2005. View Article : Google Scholar : PubMed/NCBI
15	Smits AJ, Kummer JA, Hinrichs JW, Herder GJ, Scheidel-Jacobse KC, Jiwa NM, Ruijter TE, Nooijen PT, Looijen-Salamon MG, Ligtenberg MJ, et al: EGFR and KRAS mutations in lung carcinomas in the Dutch population: Increased EGFR mutation frequency in malignant pleural effusion of lung adenocarcinoma. Cell Oncol (Dordr). 35:189–196. 2012. View Article : Google Scholar
16	Locatelli-Sanchez M, Couraud S, Arpin D, Riou R, Bringuier PP and Souquet PJ: Routine EGFR molecular analysis in non-small-cell lung cancer patients is feasible: Exons 18–21 sequencing results of 753 patients and subsequent clinical outcomes. Lung. 191:491–499. 2013. View Article : Google Scholar : PubMed/NCBI
17	Penzel R, Sers C, Chen Y, Lehmann-Mühlenhoff U, Merkelbach-Bruse S, Jung A, Kirchner T, Büttner R, Kreipe HH, Petersen I, et al: EGFR mutation detection in NSCLC - assessment of diagnostic application and recommendations of the German Panel for Mutation Testing in NSCLC. Virchows Arch. 458:95–98. 2011. View Article : Google Scholar
18	Miyamae Y, Shimizu K, Hirato J, Araki T, Tanaka K, Ogawa H, Kakegawa S, Sugano M, Nakano T, Mitani Y, et al: Significance of epidermal growth factor receptor gene mutations in squamous cell lung carcinoma. Oncol Rep. 25:921–928. 2011.PubMed/NCBI
19	Perez-Moreno P, Brambilla E, Thomas R and Soria JC: Squamous cell carcinoma of the lung: Molecular subtypes and therapeutic opportunities. Clin Cancer Res. 18:2443–2451. 2012. View Article : Google Scholar : PubMed/NCBI
20	Boch C, Kollmeier J, Roth A, Stephan-Falkenau S, Misch D, Grüning W, Bauer TT and Mairinger T: The frequency of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC): Routine screening data for central Europe from a cohort study. BMJ Open. 3:42013. View Article : Google Scholar
21	Unni AM, Lockwood WW, Zejnullahu K, Lee-Lin SQ and Varmus H: Evidence that synthetic lethality underlies the mutual exclusivity of oncogenic KRAS and EGFR mutations in lung adenocarcinoma. eLife. 4:e069072015. View Article : Google Scholar : PubMed/NCBI